Secures $50m Exclusive German Supply Agreement with ADREX
Filed with ASX · · 3 pages · English
Summary by 6ix AI
Bioxyne Limited has secured a significant supply agreement with ADREXpharma GmbH for the provision of GMP-manufactured cannabis products in Germany. This partnership enhances Bioxyne's position in the European medicinal cannabis market, particularly in Germany, which is the largest in Europe. The agreement also grants ADREX exclusive rights to distribute Bioxyne's Dr Watson® brand in Germany, supporting market penetration.
Written by 6ix AI from the company’s filing. How 6ix writes summaries
Earlier from Bioxyne
- Expands LATAM Footprint First Supply Agreement Costa Rica
- Manufacturing Agreement Aurora Supplementary Information
- Bioxyne Signs Manufacturing Agreement with Aurora Cannabis
- BXN H1 FY2026 Results Presentation
- Stronger H1 FY2026 Performance Upward Revision to Guidance
Later from Bioxyne
All Bioxyne news releasesFollow Bioxyne into a list and get an email when it puts out news.
Follow Bioxyne